secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-08-06T20:16:17+00:00
Accession:  0001104659-26-092025
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q2 net loss $14.9M; proposes all-stock merger with Avere Therapeutics
------------------------------------------------------------------------------

- Definitive all-stock merger with Avere Therapeutics; combined co to trade as AVRX; concurrent $320M private financing.
- Cash, equivalents, and marketable securities $20.1M at June 30, 2026, down from $41.8M at Dec 31, 2025.
- Net loss $14.9M for Q2 2026 vs $26.8M for Q2 2025; R&D expenses fell to $7.4M from $24.1M.
- Asset impairment costs of $5.1M from restructuring initiatives to reduce footprint and sell assets.
- LigaChem elected to continue LNCB74 development; NextCure eligible for future milestones and royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/0001104659-26-092025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926092025/nxtc-20260806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer